background

Clinical News

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

2023-03-17

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

The phase III PARADIGM trial demonstrated that hyper-selected patients with no gene alterations would tend to be more beneficial with panitumumab than bevacizumab regardless of primary tumor sidedness.

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial (Slide presentation in ASCO GI 2023)
UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

2023-03-17

UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

A retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) database was presented at the 2023 ASCO Genitourinary Cancers Symposium. Through the next generation sequencing, the study analyzed several molecular biomarkers to identify the correlation between specific biomarkers and the efficacy of enfortumab vedotin.
Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

2023-03-17

Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

The phase 1b KRYSTAL-1 and phase 2 KRYSTAL-7 studies demonstrated that the combination of adagrasib (the second KRAS G12C inhibitor to receive FDA accelerated approval) and pembrolizumab (an immune checkpoint inhibitor) had antitumor activity in patients with NSCLC.

Pasi A. Jänne presented at ESMO IMMUNO-ONCOLOGY 2022, LBA4. Pasi et al.,N Engl J Med 2022; 387:120-131
Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial

2023-02-14

Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial

There is a promising combination of neratinib plus fulvestrant plus trastzuzumab (N+F+T) to patients with HR+/HER2-/HER2mut metastatic breast cancer, who pretreated with CDK4/6 inhibitor.

1. Komal L. Jhaveri, Jonathan W. Goldman, et al. Journal of Clinical Oncology. 2022; 40, no. 16_suppl:1028-1028. 2. Eli LD, Kavuri SM. Cancer Drug Resist. 2022;5(4):873-881. 3. NCCN Clinical Practice Guidelines. Breast Cancer. Version 1.2023
Tucatinib plus trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer: Results from the phase II MOUNTAINEER trial

2023-02-14

Tucatinib plus trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer: Results from the phase II MOUNTAINEER trial

The phase II MOUNTAINEER trial demonstrated statistically significant results of tucatinib and trastuzumab combinations in RAS wild-type, HER2-positive metastatic colorectal cancer who failed with prior chemotherapy.

Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (Slide presentation in ESMO 2022)
Ripretinib demonstrated clinical benefit in gastrointestinal stromal tumors harboring KIT exon 11 and 17/18 mutations in exploratory ctDNA analysis from the phase 3 INTRIGUE trial.

2023-02-14

Ripretinib demonstrated clinical benefit in gastrointestinal stromal tumors harboring KIT exon 11 and 17/18 mutations in exploratory ctDNA analysis from the phase 3 INTRIGUE trial.

In the second-line setting, patients with KIT exon 11 + 17/18 mutations were found to be superior to sunitinib in objective response rate (ORR) and time-to-event analyses.

Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer: Results from the Phase III CAPItello-291 trial

2023-01-16

Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer: Results from the Phase III CAPItello-291 trial

The Phase III CAPItello-291 trial demonstrated statistically significant results of capivasertib plus fulvestrant in overall and the AKT pathway-altered HR+/HER2- advanced breast cancer
A novel bispecific antibody zanidatamab elicits antitumor activity in HER2-amplified and overexpressing biliary tract cancers in a phase 2b clinical trial.

2023-01-16

A novel bispecific antibody zanidatamab elicits antitumor activity in HER2-amplified and overexpressing biliary tract cancers in a phase 2b clinical trial.

Zanidatamab monotherapy demonstrated objective responses in HER2-amplified and overexpressed biliary tract cancers in the phase 2b HERIZON-BTC-01 trial.

Meric-Bernstam et al., Lancet Oncol 2022; 23: 1558–70 Zymeworks announces positive topline data in the pivotal HERIZON-BTC-01 trial of zanidatamab. News release. Zymeworks Inc. December 19, 2022. Accessed December 20, 2022. https://bit.ly/3PFJUdc